Year None2023202220212020201920182017 May 10, 2023 Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 03, 2023 Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting May 02, 2023 Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 Apr 21, 2023 Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Mar 08, 2023 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Feb 07, 2023 Tenaya Therapeutics to Participate in Upcoming Investor Conferences Jan 09, 2023 Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
May 10, 2023 Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023 Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting
Apr 21, 2023 Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 08, 2023 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
